Purpose. Rhabdomyosarcoma Results. Our analysis indicates that although p21 is wild type in RMS, there is an inverse correlation between the levels of p21 and MyoD in these tumors. Tumors that express significant amounts of MyoD fail to express p21. This does not appear to be the result of mutations within the potential CACGTG sites present in the p21 promoter region or in the coding region of p21. An additional group of RMSs express very high levels of p21 but express little, if any, MyoD. Furthermore, RD, a RMS cell line which expresses high levels of endogenous p21, undergoes withdrawal from the cell cycle following forced expression of p21, suggesting that the pathway which would lead to G1 arrest from endogenous p21 activity is defective.
Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and comprises 5-8% of all pediatric tumors. This embryonal tumor is thought to arise from poorly differentiated mesenchymal cells, with morphologic and biochemical similarities to primitive skeletal muscle cells. These tumors behave in an aggressive fashion, have a high proliferative capacity and fail to differentiate into mature muscle cells.
The mechanisms involved in the regulation of skeletal muscle differentiation have been investigated intensively. The pathways which lead to terminal differentiation appear to be coupled to those which cause withdrawal from the cell cycle and, presumably, this allows cells to maintain a differentiated state. The closely related processes of terminal differentiation and growth arrest are tightly regulated through complex mechanisms involving cyclins, cyclin-dependent kinases (CDK's) and CDK inhibitors (CDKI's). 2 Basic helix-loop-helix (HLH) transcription factors in the MyoD family induce expression of skeletal muscle specific proteins and withdrawal from the cell cycle.
An early event in the transformation process in RMS may be related to the dysregulation of the normally tightly coupled pathways of muscle differentiation and growth arrest. RMSs are known to express MyoD or other related HLH proteins, 6 yet retain their ability to proliferate and fail to differentiate terminally. It has been shown that MyoD derived from RMS cell lines is capable of binding to its cognate DNA sequences, but is unable to transactivate muscle-specific genes, suggesting that RMS cells are deficient in a factor required for MyoD activity. 7 Since MyoD activates the expression of p21 in normal developing muscle, and since we recognized the presence of potential HLH binding Correspondence to: K. G. Bhatia induces cell-cycle arrest and inhibits cell proliferation. Subsequent studies showed that, in developing skeletal muscle cells, arrest of cell proliferation is associated with increased expression of p21. Furthermore, MyoD, a member of the family of myogenic basic HLH proteins involved in induction of muscle-differentiation specific genes, can induce expression of p21. Consistent with this observation, we also identified several CACGTG sites in the regulatory region of p21. 8 Thus, p21 appears to be involved in the coupling of the two processes of cell proliferation arrest and terminal differentiation in skeletal muscle cells.
3
Since RMS is a tumor of primitive skeletal muscle cells which undergo uncontrolled proliferation and fail to differentiate terminally into normal skeletal muscle, we chose to examine p21 status in these tumors. In normal skeletal muscle cells, expression of MyoD, and other muscle-specific genes, leads to terminal differentiation and growth arrest, associated with induction of p21 expression. Expression of MyoD is also seen in the majority of cases of RMS, irrespective of their histology. 4 Tonin et al. 5 investigated the expression of several muscle-specific genes in RMS of both embryonal and alveolar subtypes. Their data suggest that RMS tumors regardless of histological features expressed MyoD 1. In the data we present ( 31 Indeed, p21 has previously been shown to suppress growth of tumor cell lines. 32 Furthermore, forced expression of p21 has been shown to reverse the abnormal proliferation of embryonal fibroblasts transformed by various oncogenes. 33 Our results support the notion that p21 plays a critical role in the normal differentiation pathway of skeletal muscle cells. In addition, our study suggests that targeted over-expression of p21 in RMS cells may correct an important biochemical defect in these cells and thus make RMS a suitable tumor for new modalities of therapy with p21.
